Patents Assigned to Xencor, Inc.
  • Patent number: 8367805
    Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
    Type: Grant
    Filed: December 22, 2008
    Date of Patent: February 5, 2013
    Assignee: Xencor, Inc.
    Inventors: Aaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • Patent number: 8362210
    Abstract: The present invention relates to novel Fc variants that comprise at least one novel amino acid residue which may provide for enhanced effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more Fc receptor or ligand (e.g., Fc gamma R, C1q). Additionally, the Fc variants have altered complement dependent cytotoxicity (CDC) activity and/or antibody-dependent cell-mediated cytotoxicity (ADCC). The invention further provides methods and protocols for the application of said Fc variants, particularly for therapeutic purposes.
    Type: Grant
    Filed: January 19, 2011
    Date of Patent: January 29, 2013
    Assignee: Xencor, Inc.
    Inventors: Gregory A. Lazar, Sher Bahadur Karki, Gregory L. Moore
  • Patent number: 8338574
    Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
    Type: Grant
    Filed: February 1, 2010
    Date of Patent: December 25, 2012
    Assignee: Xencor, Inc.
    Inventors: Aaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • Publication number: 20120321620
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Application
    Filed: August 24, 2012
    Publication date: December 20, 2012
    Applicant: XENCOR, INC.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • Patent number: 8329867
    Abstract: The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
    Type: Grant
    Filed: February 22, 2011
    Date of Patent: December 11, 2012
    Assignee: Xencor, Inc.
    Inventors: Gregory A. Lazar, Matthew J. Bernett
  • Patent number: 8324351
    Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
    Type: Grant
    Filed: February 1, 2010
    Date of Patent: December 4, 2012
    Assignee: Xencor, Inc.
    Inventors: Aaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • Patent number: 8318907
    Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
    Type: Grant
    Filed: February 1, 2010
    Date of Patent: November 27, 2012
    Assignee: Xencor, Inc.
    Inventors: Aaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • Patent number: 8314213
    Abstract: The present invention is directed to the creation of human equivalent CDRs and antibodies containing them by a method of producing an antibody which specifically binds to an antigen.
    Type: Grant
    Filed: April 20, 2009
    Date of Patent: November 20, 2012
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Gregory Moore, John R. Desjarlais
  • Publication number: 20120258092
    Abstract: The present invention relates to optimized CD20 antibodies having Fc variants, methods for their generation, and method for their application, such as methods of enhancing macrophage activation, particularly for therapeutic purposes.
    Type: Application
    Filed: December 23, 2011
    Publication date: October 11, 2012
    Applicant: Xencor, Inc.
    Inventors: Bassil I. Dahiyat, Gregory A. Lazar, Omid Vafa
  • Publication number: 20120230980
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Application
    Filed: January 9, 2012
    Publication date: September 13, 2012
    Applicant: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John Rudolph Desjarlais, Stephen Kohl Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • Publication number: 20120225058
    Abstract: An Fc variant of a parent Fc polypeptide, wherein said Fc variant exhibits altered binding to one or more Fc?Rs, wherein said Fc variant comprises at least one amino acid insertion in the Fc region of said parent Fc polypeptide.
    Type: Application
    Filed: December 23, 2011
    Publication date: September 6, 2012
    Applicant: Xencor, Inc.
    Inventors: Gregory A. Lazar, Bassil I. Dahiyat, Wei Dang, Sher Bahadur Karki, Omid Vafa
  • Publication number: 20120156220
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Application
    Filed: November 21, 2011
    Publication date: June 21, 2012
    Applicant: Xencor, Inc.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • Publication number: 20120156207
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Application
    Filed: November 10, 2011
    Publication date: June 21, 2012
    Applicant: Xencor, Inc.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • Publication number: 20120148578
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Application
    Filed: November 21, 2011
    Publication date: June 14, 2012
    Applicant: XENCOR, INC.
    Inventors: SEUNG YUP CHU, JOHN R. DESJARLAIS, SHER BAHADUR KARKI, GREGORY ALAN LAZAR, GREGORY L. MOORE, IGOR VOSTIAR
  • Patent number: 8188231
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Grant
    Filed: May 5, 2005
    Date of Patent: May 29, 2012
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Wei Dang, John R. Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • Publication number: 20120128663
    Abstract: The invention relates generally to compositions and methods for altering the serum half-life in vivo of an antibody.
    Type: Application
    Filed: October 12, 2011
    Publication date: May 24, 2012
    Applicant: Xencor, Inc.
    Inventor: Gregory A. Lazar
  • Publication number: 20120088905
    Abstract: The present application relates to a variant Fc region comprising the double mutation 428L/434S that increases serum half-life and the numbering is according to the EU index.
    Type: Application
    Filed: December 15, 2011
    Publication date: April 12, 2012
    Applicant: XENCOR, INC.
    Inventors: AARON KEITH CHAMBERLAIN, BASSIL I. DAHIYAT, JOHN R. DESJARLAIS, SHER BAHADUR KARKI, GREGORY ALAN LAZAR
  • Patent number: 8124731
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: February 28, 2012
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John R. Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • Publication number: 20120028304
    Abstract: The invention relates generally to compositions and methods for altering the isoelectric point of an antibody, and in some cases, resulting in improved plasma pharmacokinetics, e.g. increased serum half-life in vivo.
    Type: Application
    Filed: July 29, 2011
    Publication date: February 2, 2012
    Applicant: XENCOR, INC.
    Inventors: Bassil I. Dahiyat, Gregory A. Lazar, Matthew J. Bernett
  • Patent number: 8101720
    Abstract: An Fc variant of a parent Fc polypeptide, wherein said Fc variant exhibits altered binding to one or more Fc?Rs, wherein said Fc variant comprises at least one amino acid insertion in the Fc region of said parent Fc polypeptide.
    Type: Grant
    Filed: January 25, 2008
    Date of Patent: January 24, 2012
    Assignee: Xencor, Inc.
    Inventors: Gregory A. Lazar, Bassil I. Dahiyat, Wei Dang, Sher Bahadur Karki, Omid Vafa